Solventum (NYSE:SOLV) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Key Points

• Solventum reported EPS of $1.45, beating the $1.34 consensus, while revenue of $1.95 billion also topped expectations of $1.93 billion.
• Despite the beat, reported sales fell 7% and organic sales declined 2.8%, largely reflecting the reversal of customer advance orders tied to an ERP cutover; management estimated normalized organic growth at about 4%.
• The company raised its 2026 outlook, now expecting EPS of $7.20–$7.30 and organic sales growth toward the high end of its 2.5%–3% range.

Solventum (NYSE:SOLV - Get Free Report) posted its earnings results on Thursday. The company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.11, FiscalAI reports. The company had revenue of $1.95 billion for the quarter, compared to analysts' expectations of $1.93 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%.

Here are the key takeaways from Solventum's conference call:

• Q3 sales were $1.95 billion, down 7% reported and 2.8% organically, including a 630-basis-point headwind from the planned reversal of ERP-related advance orders. Management said normalized organic growth was about 4%; EPS was $1.45, including an estimated $0.35 impact from the timing reversal.
• Solventum raised its 2026 outlook, now expecting organic sales growth toward the high end of its 2.5%–3% range and EPS of $7.20–$7.30, up from $7.10–$7.20. Operating margin is expected toward the high end of its 22.2%–22.7% range.
• The company completed its largest ERP cutover and said its separation from 3M is more than 90% complete, with the remaining transition services expected to end by the close of 2027. A renegotiated supply agreement also removes a previously anticipated 100-basis-point gross-margin headwind beginning in 2027; management expects separation costs to step down, supporting free cash flow.
• Solventum is evaluating a sale or spin-off of Health Information Systems (HIS), with timing and structure still undecided. Management estimates the separation would cause about 400 basis points of annualized net operating margin dilution, though it expects to use proceeds first to pay down debt and then return most remaining proceeds to shareholders.
• Management highlighted growth opportunities from underpenetrated products, new launches, and acquisitions, including V.A.C. wound therapy and Acera. Acera grew 35% and had its best quarter on record, while the company said its combined-use clearance for Restrata and V.A.C. enables joint marketing.

Solventum Stock Performance

Shares of NYSE SOLV traded down $2.44 during trading on Thursday, reaching $86.91. 1,880,645 shares of the company traded hands, compared to its average volume of 1,303,519. The firm has a 50 day simple moving average of $87.75 and a 200-day simple moving average of $78.64. Solventum has a 52-week low of $62.38 and a 52-week high of $94.16. The stock has a market capitalization of $14.79 billion, a PE ratio of 10.63, a P/E/G ratio of 1.24 and a beta of 0.69. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00.

Wall Street Analysts Forecast Growth

SOLV has been the subject of several research analyst reports. Jefferies Financial Group restated a "buy" rating on shares of Solventum in a report on Thursday, October 8th. BMO Capital Markets initiated coverage on shares of Solventum in a research note on Wednesday, July 8th. They issued a "market perform" rating and a $81.00 price target for the company. Wall Street Zen raised shares of Solventum from a "hold" rating to a "buy" rating in a research note on Saturday, September 12th. Mizuho set a $113.00 target price on shares of Solventum in a report on Thursday, August 6th. Finally, UBS Group upped their price target on Solventum from $95.00 to $101.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Ten equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Solventum currently has a consensus rating of "Moderate Buy" and an average price target of $87.55.

Trending Headlines about Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Adjusted earnings were $1.45 per share, ahead of analyst estimates of $1.34–$1.35, and revenue of $1.95 billion also topped expectations. Solventum raised its FY2026 adjusted EPS outlook to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Reports Third Quarter 2026 Financial Results
• Negative Sentiment: Reported sales fell 7.0% year over year, while organic sales declined 2.8%. The company attributed the organic decrease partly to a 630-basis-point impact from customers’ advance orders in the prior quarter ahead of an ERP system cutover. Coverage also described the quarter as a loss on a reported basis, despite the adjusted earnings beat. Solventum Posts Q3 Loss; Raises FY26 Adjusted EPS Outlook
• Negative Sentiment: Higher raw-material costs remain a concern, potentially tempering the benefit of growth investments and cost-saving efforts. Here's Why You Should Hold Solventum Stock in Your Portfolio for Now

Solventum Company Profile

Solventum Corporation NYSE: SOLV is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company's portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.